MOORESTOWN, N.J., April 5, 2019 — Tabula Rasa HealthCare, Inc. (TRHC) (NASDAQ: TRHC), a healthcare technology company advancing the field of medication safety, today announced that its newly-acquired precision dosing software company DoseMe completed the country’s first fully-integrated Precision Dosing Software solution for one of the nation’s leading health care providers with multiple locations in Florida.
DoseMeRx™ integrated with market leading hospital electronic health record providers, allows hospital users to swiftly, easily, and securely launch independent applications from the hospital’s own system using de-identified information. Utilizing industry leading software language, commonly referred to as SMART-on-FHIR, hospitals access TRHC’s clinical decision support software to individualize the dose of medications to help healthcare professionals easily optimize therapy for each patient, resulting in improvements to mortality, risk and patient outcomes, as well as saving hours of pharmacist time performing manual calculations.
“We are pleased with the traction our recently-acquired DoseMeRx is garnering in the United States in helping patients with precision, parenteral pharmacotherapy,” said TRHC Chairman and CEO Calvin H. Knowlton, PhD. “We believe this trend will continue as hospitals and healthcare systems become more patient-centered and realize the clinical and economic benefits of incorporating DoseMeRx into their narrow-therapeutic index drug protocols.”
TRHC’s focus is on providing solutions for individualizing the dose of medications to help healthcare professionals easily optimize therapy for each patient, resulting in improvements to mortality, risk and patient outcomes. TRHC’s technology now supports dose optimization for tens of thousands of patients, for more than 1,250 clinicians and across more than 130 locations world-wide.
“Being the world’s leading precision dosing software comes with the responsibility of advancing the access and utility of such solutions. We have known for some time that we were ahead of the market in promoting integrated clinical decision support software (CDSS) within the acute hospital setting; so, to go live with such a prestigious group, one that is known as an innovator and a leader in clinical care makes it so worthwhile. Our organization is built around three fundamental elements – great science, clinical importance and brilliant usability. This integration brings these elements together, resulting in improved workflows, cost savings and better patient outcomes, all while empowering the pharmacist to be her or his best,” said Charles Cornish, Chief Executive Officer of DoseMe.
About DoseMe
DoseMe is a Tabula Rasa HealthCare Company (NASDAQ: TRHC) and the first company in the world to develop precision dosing software – DoseMeRx – developed specifically for clinical practice. DoseMe’s clinical decision support solutions focus on empowering healthcare providers to optimize dosing of high-risk parenteral medications to streamline operations, reduce adverse drugs events, decrease costs and improve patient outcomes.
Forward-Looking Statements
This press release includes forward-looking statements that we believe to be reasonable as of today’s date, including statements regarding Medication Risk Mitigation technology. Such statements are identified by use of the words “anticipates,” “believes,” “estimates,” “expects,” “intends,” “plans,” “predicts,” “projects,” “should,” and similar expressions. These forward-looking statements are based on management’s expectations and assumptions as of the date of this press release. Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include: the need to innovate and provide useful products and services; risks related to changing healthcare and other applicable regulations; increasing consolidation in the healthcare industry; managing our growth effectively; our ability to adequately protect our intellectual property; and the other risk factors set forth from time to time in our filings with the SEC, including those factors discussed under the caption “Risk Factors” in our most recent annual report on Form 10-K, filed with the SEC on March 1, 2019, and in subsequent reports filed with or furnished to the SEC, copies of which are available free of charge within the Investor Relations section of the TRHC website or upon request from our Investor Relations Department. Any forward-looking statement speaks only as of the date on which it was made. TRHC assumes no obligation and does not intend to update these forward-looking statements, except as required by law, to reflect events or circumstances occurring after today’s date.